2020's been a mixed bag for the Buccaneers QB. Can he draw up a 300-yard game in Las Vegas?
2020's been a mixed bag for the Buccaneers QB. Can he draw up a 300-yard game in Las Vegas?
More than 30 people were charged for their participation in a test score-fixing scheme that happened over seven years at a United States Coast Guard exam center in Louisiana, federal prosecutors announced. The indictment centers around Dorothy Smith, a former employee at an exam center in Mandeville, who was required to enter scores for exams merchant mariners were required to pass to get licenses for positions on ships, the U.S. Attorney’s Office for the Eastern District of Louisiana said Monday in a news release. The release said those intermediaries would funnel the money and the mariners’ requests to Smith, who would then falsely report the scores in the Coast Guard computer system.
The College Football Playoff put out a news release to get fans ready for the season's first selection committee rankings Tuesday night. The takeaway: It's business as usual for the CFP, even if this college football season has been anything but. There is one odd pattern: The team ranked third in the committee's first rankings of the season has never made the playoff, including Alabama last year.
China Petroleum & Chemical Corporation (HKG: 0386, "Sinopec") has established strategic cooperation with three top institutions on November 23 in Beijing, China, to take lead in a joint research on the energy and chemical industry's carbon emissions peak and carbon neutral.
Our guide to all the latest Shark vacuum deals for Black Friday 2020, including all the top deals on Shark Navigator, VACMOP, IQ robot vacuum & more
In their mission to handle the COVID-19 crises and provide economic relief, the government through the COVID-19 Handling and National Economic Recovery Committee (KPCPEN) has focused their efforts on educating the public on the importance of a vaccination program to combat COVID-19. To reinforce their efforts, the government has identified the co-operation of the mass media to play a crucial role, hence inviting them to carry out their role as the fourth pillar of democracy by publishing accurate and factual news on the COVID-19 vaccination program.
The Spending Review marks the start of the chancellor's economic recovery planning. Here's what to watch for.
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Nasal delivery devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Type; Delivery Technologies; End User, and Geography" report has been added to ResearchAndMarkets.com's offering. The market is expected to reach US$ 95,676.62 million by2027 from US$ 58,502.18 million in 2019. The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027. Based on delivery technologies, the market is segmented in to spray, nebulizers, inhalers, and others. In 2019, the inhalers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period. An inhaler (also known as a pump, puffer, or allergy spray) is a nasal delivery device used for delivering medicines into the lungs via person's breathing mechanism. This device helps deliver medical treatment to the targeted region of the body, thereby reducing the side effects of oral medications. There are a wide variety of inhalers that are used to treat numerous medical conditions, such as asthma and chronic obstructive pulmonary disease (COPD). Some of the common types of inhalers include meter-dosed inhalers, dry powder inhalers, soft mist inhalers, and others. There are certain types of inhalers containing drugs in it for the treatment of asthma and COPD such as , reliever inhalers: contain bronchodilator medicines, preventer inhalers: contain a steroid medicine. GlaxoSmithKline plc.; AstraZeneca; Pfizer Inc.; BD; Sanofi; Merck & Co.Inc.; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories; and Neurelis, Inc. are among the leading companies operating in the nasal delivery devices market. Key Topics Covered: 1\. Introduction 1.1 Scope of the Study 1.2 Report Guidance 1.3 Market Segmentation 2\. Nasal Delivery Devices Market - Key Takeaways 3\. Research Methodology 4\. Global Nasal Delivery Devices Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.3 Expert Opinion 5\. Nasal Delivery Devices Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Growing Prevalence of Respiratory and CNS Diseases 5.1.2 Increasing Preference and Awareness Among Patients 5.2 Market Restraints 5.2.1 Challenges Associated with Nasal Administration of Drugs 5.3 Market Opportunities 5.3.1 Rising Adoption of Self-Administration Practices 5.4 Future Trends 5.4.1 Consolidation of Nasal Delivery Device Industry 5.5 Impact Analysis 6\. Nasal Delivery Devices Market - Global Analysis 6.1 Global Nasal Delivery Devices Market Revenue Forecast And Analysis 6.2 Global Nasal Delivery Devices Market, By Geography - Forecast And Analysis 6.3 Market Positioning of Key Players 7\. Nasal Delivery Devices Market Analysis - By Drug Type 7.1 Overview 7.2 Nasal Delivery Devices Market Revenue Share, by Drug Type (2019 and 2027) 7.3 Anesthetics 7.3.1 Overview 7.3.2 Anesthetics: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million) 7.4 Antibiotics 7.5 Pain Relief Drugs 7.6 Calcium Supplements 7.7 Vasoconstrictors 7.8 Antihistamines 8\. Nasal Delivery Devices Market Analysis - By Delivery Technologies 8.1 Overview 8.2 Nasal Delivery Devices Market Revenue Share, by Delivery Technologies (2019 and 2027) 8.3 Spray 8.3.1 Overview 8.3.2 Spray: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million) 8.4 Nebulizers 8.5 Inhalers 9\. Nasal Delivery Devices Market Analysis - By End -User 9.1 Overview 9.2 Nasal Delivery Devices Market Revenue Share, by End -User (2019 and 2027) 9.3 Home Care Setting 9.3.1 Overview 9.3.2 Home Care Setting: Nasal Delivery Devices - Revenue and Forecast to 2027 (US$ Million) 9.4 Hospitals 9.5 Clinics 10\. Nasal Delivery Devices Market - Geographic Analysis 11\. Impact of COVID-19 Pandemic on Global Nasal Delivery Devices Market 12\. Nasal Delivery Devices Market- Industry Landscape 12.1 Overview 12.2 Growth Strategies Done by the Companies in the Market, (%) 12.3 Organic Developments 12.4 Inorganic Developments 13\. Company Profiles 13.1 Key Facts 13.2 Business Description 13.3 Products and Services 13.4 Financial Overview 13.5 SWOT Analysis 13.6 Key Developments * GlaxoSmithKline plc. * AstraZeneca * Pfizer Inc. * BD * Sanofi * Merck & Co., Inc. * Cadila Pharmaceuticals Ltd. * Novartis AG * Dr. Reddy's Laboratories * Neurelis, Inc.For more information about this report visit https://www.researchandmarkets.com/r/v0xqp0Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Annette Guzman-Torres was feeling discouraged and frustrated, her anxiety fueled by the uncertainty of a bleak job market during the coronavirus pandemic. The 44-year-old married mother of two boys is close to finishing the capstone project for her doctorate from Capella University. “I was like, I have no job, nowhere to go, nothing to do,” said the resident of Bloomfield, New Jersey.
Directors had set up rescue refinancing but investors demand better deal
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Tryg A/S, has received the following information from Danske Bank A/S and Morgan Stanley & Co. International plc:Further to the announcement on 23 November 2020, Danske Bank A/S (“Danske Bank”) and Morgan Stanley & Co. International plc (“Morgan Stanley”) (together “the Managers”) announce that TryghedsGruppen smba (“TryghedsGruppen”) has agreed to sell 21,149,745 existing shares in Tryg A/S (“Tryg”), equivalent to 7% of the existing shares in Tryg to institutional investors at a price of DKK 170 per share, pursuant to an accelerated bookbuild offering (the “Transaction”). Danske Bank and Morgan Stanley acted as Joint Global Coordinators and Joint Bookrunners in the Transaction. Following settlement of the Transaction (which is subject to customary closing conditions and expected to be on 26 November 2020), TryghedsGruppen will hold 53% of the existing shares in Tryg. In connection with the Transaction, TryghedsGruppen has undertaken to the Managers that, subject to certain exceptions, for a specific period of time (the “Lock-Up Period”) it will not dispose of any Tryg shares which are not sold in the Transaction without the prior written consent of the Managers. The Lock-Up Period means the shorter of (i) 180 calendar days from the first day of trading of any new Tryg shares in the ISIN code of its existing shares, that may be issued in connection with the Rights Issue; and (ii) 365 calendar days after the date of 23 November 2020. Tryg will not receive any proceeds from the Transaction.Contact information Gianandrea Roberti, Investor Relations Officer +45 20 18 82 67 firstname.lastname@example.org Peter Brondt, Investor Relations Manager +45 22 75 89 04 email@example.com Tanja Frederiksen, Head of Communications +45 51 95 77 78 firstname.lastname@example.orgImportant Information THIS ANNOUNCEMENT DOES NOT CONSTITUTE, OR FORM PART OF, AN OFFER TO SELL, OR A SOLICITATION OF AN OFFER TO PURCHASE ANY SECURITY IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES EXCEPT TO “QUALIFIED INSTITUTIONAL BUYERS” AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT. ALL OFFERS AND SALES OF SECURITIES OUTSIDE OF THE UNITED STATES WILL BE MADE IN RELIANCE ON, AND IN COMPLIANCE WITH, REGULATION S UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO MAKE A PUBLIC OFFERING OF THE SECURITIES IN THE UNITED STATES. THE SECURITIES MAY NOT AND WILL NOT BE OFFERED OR SOLD IN CANADA, JAPAN AND AUSTRALIA. WITH RESPECT TO THE MEMBER STATES OF THE EUROPEAN ECONOMIC AREA SUBJECT TO REGULATION 2017/1129/EU (TOGETHER WITH ANY APPLICABLE IMPLEMENTING MEASURES, THE “PROSPECTUS REGULATION”) (EACH A “RELEVANT MEMBER STATE”), NO ACTION HAS BEEN UNDERTAKEN OR WILL BE UNDERTAKEN TO MAKE AN OFFER TO THE PUBLIC OF THE SECURITIES REFERRED TO HEREIN REQUIRING THE PUBLICATION OF A PROSPECTUS IN ANY RELEVANT MEMBER STATE. AS A RESULT, THESE SECURITIES MAY ONLY BE OFFERED OR SOLD IN ANY RELEVANT MEMBER STATE PURSUANT TO AN EXEMPTION UNDER THE PROSPECTUS REGULATION. THIS ANNOUNCEMENT IS ONLY ADDRESSED TO, AND DIRECTED AT, PERSONS IN RELEVANT MEMBER STATES OF THE EUROPEAN ECONOMIC AREA WHO ARE “QUALIFIED INVESTORS” WITHIN THE MEANING OF ARTICLE 2(e) OF THE PROSPECTUS REGULATION (“QUALIFIED INVESTORS”). IN THE UNITED KINGDOM, THIS ANNOUNCEMENT IS DIRECTED ONLY AT, QUALIFIED INVESTORS (I) WHO ARE “INVESTMENT PROFESSIONALS” FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE “ORDER”), OR (II) PERSONS FALLING WITHIN ARTICLE 49(2)(A)-(D) (“HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC”) OF THE ORDER ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS (“RELEVANT PERSONS”). UNDER NO CIRCUMSTANCES SHOULD PERSONS WHO ARE NOT RELEVANT PERSONS RELY OR ACT UPON THE CONTENTS OF THIS ANNOUNCEMENT. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IN THE UNITED KINGDOM IS AVAILABLE ONLY TO, AND WILL BE ENGAGED ONLY WITH, RELEVANT PERSONS. IN DENMARK, THIS PRESS RELEASE IS DIRECTED ONLY AT PERSONS WHO ARE QUALIFIED INVESTORS. DANSKE BANK AND MORGAN STANLEY ARE ACTING FOR TRYGHEDSGRUPPEN AND FOR NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN TRYGHEDSGRUPPEN FOR PROVIDING THE PROTECTIONS AFFORDED TO CUSTOMERS OF DANSKE BANK AND MORGAN STANLEY OR FOR AFFORDING ADVICE IN RELATION TO THE TRANSACTION, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO IN THIS ANNOUNCEMENT. EITHER OF THE MANAGERS MAY PARTICIPATE IN THE TRANSACTION ON A PROPRIETARY BASIS. THIS ANNOUNCEMENT HAS BEEN ISSUED BY DANSKE BANK AND MORGAN STANLEY ON BEHALF OF TRYGHEDSGRUPPEN AND IS THE SOLE RESPONSIBILITY OF TRYGHEDSGRUPPEN. APART FROM THE RESPONSIBILITIES AND LIABILITIES, IF ANY, THAT MAY BE IMPOSED ON MORGAN STANLEY BY THE FINANCIAL SERVICES AND MARKETS ACT 2000, DANSKE BANK AND MORGAN STANLEY DO NOT ACCEPT ANY RESPONSIBILITY WHATSOEVER AND MAKE NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, FOR THE CONTENTS OF THIS ANNOUNCEMENT, INCLUDING ITS ACCURACY, COMPLETENESS OR VERIFICATION OR FOR ANY OTHER STATEMENT MADE OR PURPORTED TO BE MADE BY TRYGHEDSGRUPPEN, OR ON TRYGHEDSGRUPPEN’S BEHALF, OR BY DANSKE BANK AND MORGAN STANLEY OR ON DANSKE BANK AND MORGAN STANLEY’S BEHALF, IN CONNECTION WITH TRYGHEDSGRUPPEN OR THE TRANSACTION, AND NOTHING IN THIS ANNOUNCEMENT IS OR SHALL BE RELIED UPON AS A PROMISE OR REPRESENTATION IN THIS RESPECT, WHETHER AS TO THE PAST OR FUTURE. DANSKE BANK AND MORGAN STANLEY ACCORDINGLY DISCLAIM TO THE FULLEST EXTENT PERMITTED BY LAW ALL AND ANY RESPONSIBILITY AND LIABILITY, WHETHER ARISING IN TORT, CONTRACT OR OTHERWISE, WHICH THEY MIGHT OTHERWISE HAVE IN RESPECT OF THIS DOCUMENT AND ANY SUCH STATEMENT.Attachment * 16_2020_Sale of 21,149,745 existing shares in Tryg
Britain's test and trace system needs to be improved, transport minister Grant Shapps said on Tuesday, adding that the government had no choice but spend a lot of money on it during the coronavirus crisis. "We have to get through this coronavirus and I'm afraid there has been no other option but to spend a lot of money," Shapps told Sky News. "We've said that we want test and trace to be a lot better."
Black Friday iRobot Roomba deals for 2020, including Roomba s9, s9+, i7, 980 & more robovac deals
The government has announced a maximum of 4,000 fans will be allowed in low-risk areas.
Retailers have begun sales earlier than ever this year, so we’ve found all the top bargains here
These are the big savings to take advantage of, from headphones to fitness trackers
Follow the latest updates
ANNOUNCEMENT NO. 101 - 24 NOVEMBER 2020In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90.Kind regards,Dampskibsselskabet NORDEN A/SMartin BadstedCFOFor further information:Martin Badsted, CFO, tel.: +45 3315 0451Attachments * No. 101 Managers' transactions * Transactions by persons discharging managerial responsibilities and persons
Lionel Messi might be a Manchester man after all.
Children in crisis: Councils an ‘invisible crisis’ played out during lockdown as social workers warn surge in domestic violence, alcohol abuse and anxiety has put caseloads at an all-time high
Every Premier League fixture for the 2020/21 season plus confirmed dates and kick-off times